Drugs
Takeda NDA for Eosinophilic Esophagitis Drug Accepted
FDA has accepted for priority review a Takeda Pharmaceutical NDA for Eohilia (budesonide oral suspension) for treating eosinophilic esophagitis (EoE), a chronic inflammatory disease that can cause damage to the esophagus. The NDA is based on data from the pivotal Phase 3 trials ORBIT1 and ORBIT2, which investigated the safety